![]() |
|||||||||||
Home | Founder | What's New | In The News | Contact Us | |||||||
![]() |
|||||||||||
Paradigm Shift Intervention Monitoring | Audio: Jan28 Apr21 Sep22
![]() ![]() Commentary H1N1
Tamiflu Resistance Vax Evasion Recently
released HA and NA sequences and phylograms define the recent emergence
and evolution of oseltamivir (Tamiflu) resistance in H1N1. The
presence of H274Y in influenza from hosts in the absence of oseltamivir
began with H5N1 in wild birds in 2005, followed by various H1N1
sub-clades in patients. Initial isolates were clade 2C (Hong
Kong/2562) in the 2005/2006 season in China, followed by clade 1 (New
Caledonia/20) in 2006/2007 in the United States, followed by clade 2B
(Brisbane/59) in the United States, which then led to a dominant clade
2B sub-clade which accounted for most cases in the United States and
Europe (supported by recently released sequences from France and
Luxembourg). Recent data demonstrates the spread
of this sub-clade into the Southern Hemisphere and the frequency of
H274Y in H1N1 is now approaching
100% in many countries. Although
the new H1N1 vaccine now targets clade 2B, the recent sequences from
South Africa had a cluster
of changes surrounding the receptor binding domain at position190 (H3
numbering). These changes are being facilitated by
recombination. The two changes on the 3’ side of the cluster are
found in H1N1 isolates from the 1940’s,
while the change at the 5’ end of the cluster is rare, but now has
appeared in recent clade 2B isolates in South Africa and the
Seychelles, but has also been found in clade 2C in Hong Kong. Media Links |
||||||||||
|
Webmaster:
webmaster@recombinomics.com
© 2008
Recombinomics. All
rights
reserved.